London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape
Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and human-centric in vitro models.
Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and human-centric in vitro models.
What's Your Reaction?
